Sutro Biopharma
Cell-free protein synthesis ADC company that refocused on exatecan and dual-payload ADCs, deprioritising its folate-receptor ADC luveltamab.
STRO-004 (tissue factor, DAR8 TOP1 payload) is the lead, with first clinical data expected mid-2026; STRO-227 is a DAR10 dual-payload PTK7 ADC (MMAE DAR2 + TOP1 DAR8) with IND planned 2026. Luveltamab tazevibulin (FRα) development stopped pending a partner. Site-specific conjugation via non-natural amino acids (XpressCF).
Pages like this
not linked directly; found by shared links- IdeaDual-payload ADCs in first line to prevent resistance
Shares Dual-payload ADC, Site-specific conjugation & linker chemistry, Acquired resistance to every therapy, Antibody-drug conjugate (ADC).
- IdeaSequence folate-receptor ADCs by payload class
Shares Luveltamab tazevibulin, Folate receptor alpha, Ovarian cancer.
- CompanyTubulis (Gilead)
Shares Site-specific conjugation & linker chemistry, Ovarian cancer, Antibody-drug conjugate (ADC).
- TrialinnovaTV 301 / ENGOT-cx12 / GOG-3057
- TrialRAINFOL-01 (Rina-S)
Shares Folate receptor alpha, Ovarian cancer, Antibody-drug conjugate (ADC).
- TrialMIRASOL / GOG-3045
Shares Folate receptor alpha, Ovarian cancer, Antibody-drug conjugate (ADC).
- ProductRinatabart sesutecan
Shares Folate receptor alpha, Ovarian cancer, Antibody-drug conjugate (ADC).
- InstitutionStephenson Cancer Center, OU Health
Shares Folate receptor alpha, Ovarian cancer, Antibody-drug conjugate (ADC).